NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life
science tools for translational research and molecular diagnostic
products, today announced the highlights of more than 40
nCounter®-based research abstracts that will be presented at the
60th Annual Meeting of the American Society of Hematology being
held December 1-4, in San Diego.
"We’re excited to see the extensive body of
nCounter-based clinical and research studies that will be presented
by our customers and collaborators at the ASH conference," said
Brad Gray, president and chief executive officer of NanoString.
"These studies illustrate how the nCounter platform may be used to
subtype lymphomas and optimize treatment regimens to contribute to
better clinical outcomes for patients."
The ASH Annual Meeting will include at least 14
oral presentations and more than 25 posters in various leukemia,
lymphoma, and myeloma malignancies that demonstrate the utility of
the nCounter platform across the heme-oncology spectrum.
These include 14 abstracts highlighting the potential clinical
utility of NanoString’s nCounter Dx LymphMark™ Lymphoma Subtyping
Test (LST) for directing treatment decisions, as well as multiple
abstracts highlighting the relevance of the PanCancer IO360™ panel
in leukemia and multiple new gene signatures on the nCounter
platform. Several important abstracts are summarized below:
The table below includes a selection of 2018 ASH abstracts that
best illustrate the potential clinical utility of nCounter across
multiple tumor types. To learn more about the capabilities of the
nCounter platform, please visit NanoString at booth #2041 at
ASH.
Abstract # |
Title |
Hyperlink |
1576 |
Elevated LAG-3 Expression in the Tumor Microenvironment of Patients
with DLBCL Is Associated with a Non-GCB Phenotype and Poor
Prognosis |
https://ash.confex.com/ash/2018/webprogram/Paper112830.html |
676 |
Integration of NanoString Profiling and Functional Characterization
of Oxidative and Replicative Stress Biomarkers Identifies Poor
Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell
Lymphoma Subsets, Providing Opportunities for Precision
Therapies |
https://ash.confex.com/ash/2018/webprogram/Paper118329.html |
764 |
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific
Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid
Leukemia (AML) |
https://ash.confex.com/ash/2018/webprogram/Paper117085.html |
444 |
Adaptive Immune Gene Signatures Correlate with Response to
Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in
Patients with Relapsed/Refractory Acute Myeloid Leukemia |
https://ash.confex.com/ash/2018/webprogram/Paper111539.html |
1627 |
Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell
Lymphoma in a Phase 1/2 Clinical Trial |
https://ash.confex.com/ash/2018/webprogram/Paper118204.html |
1560 |
Molecular and Genetic Characterization of MHC Deficiency Identifies
EZH2 As a Therapeutic Target for Restoring MHC Expression in
Diffuse Large B-Cell Lymphoma |
https://ash.confex.com/ash/2018/webprogram/Paper112010.html |
921 |
The Double-Hit Gene Expression Signature Defines a Clinically and
Biologically Distinct Subgroup within GCB-DLBCL |
https://ash.confex.com/ash/2018/webprogram/Paper116827.html |
1567 |
Large B-Cell Lymphomas in Pediatric and Young Adults Display
Clinically Relevant Molecular Features Distinguishable from Adult
Counterparts |
https://ash.confex.com/ash/2018/webprogram/Paper114493.html |
2896 |
Durable Responses with
Pembrolizumab in Relapsed/Refractory Mycosis Fungoides
and Sézary Syndrome: Final Results from a Phase 2 Multicenter
Study |
https://ash.confex.com/ash/2018/webprogram/Paper117244.html |
346 |
New Genomic Model Integrating Clinical Factors and Gene Mutations
to Predict Overall Survival in Patients with Diffuse Large B-Cell
Lymphoma Treated with R-CHOP |
https://ash.confex.com/ash/2018/webprogram/Paper117636.html |
2962 |
High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in
First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using
Gene-Expression Prophyling: A Combined Analysis from Two Phase 2
Trials |
https://ash.confex.com/ash/2018/webprogram/Paper119495.html |
1688 |
Multicenter Phase II Trial Addressing Lenalidomide Maintenance in
Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who
Are Not Eligible for Autologous Stem Cell Transplantation (ASCT):
Efficacy and Safety Results after a Median Follow-up of Five
Years |
https://ash.confex.com/ash/2018/webprogram/Paper116060.html |
782 |
Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin,
Vincristine and Prednisolone (R-CHOP) Improves Outcomes in
BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL):
First Safety, Efficacy and Biomarker Analyses from the Phase II
CAVALLI Study |
https://ash.confex.com/ash/2018/webprogram/Paper118519.html |
2959 |
Primary Mediastinal B-Cell Lymphoma: Evaluation of
Clinicopathologic Diagnosis Compared to Gene Expression Based
Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas |
https://ash.confex.com/ash/2018/webprogram/Paper115024.html |
3091 |
Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in
Patients with TP53 mutant Myelodysplastic Syndromes (MDS)
and Acute Myeloid Leukemia (AML) |
https://ash.confex.com/ash/2018/webprogram/Paper119990.html |
1561 |
Prediction and Characterization of Diffuse Large B-Cell Lymphoma
(DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from
Targeted Next-Generation Sequencing |
https://ash.confex.com/ash/2018/webprogram/Paper116677.html |
929 |
Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for
Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of
PET-Adapted Approach |
https://ash.confex.com/ash/2018/webprogram/Paper113034.html |
1683 |
Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R)
or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large
B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II
Study |
https://ash.confex.com/ash/2018/webprogram/Paper118551.html |
669 |
Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma
Lead to an Altered Gene Expression Profile and Changes in Tumor
Microenvironment Composition |
https://ash.confex.com/ash/2018/webprogram/Paper110473.html |
1845 |
Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic
Leukemia Are Associated with VH1-69: Linking B-Cell Receptor
Stereotypy to Downstream Signaling Events |
https://ash.confex.com/ash/2018/webprogram/Paper116293.html |
2927 |
Potential Impact of Consolidation Radiation Therapy for Advanced
Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver
Operating Characteristic Analysis |
https://ash.confex.com/ash/2018/webprogram/Paper113133.html |
2397 |
The Role of microRNAs in the Pathogenesis of Erdheim-Chester
Disease and Their Potential Use As Biomarkers for Diagnosis and
Prognosis of the Disease |
https://ash.confex.com/ash/2018/webprogram/Paper112388.html |
1593 |
Five-Year Outcomes of SWOG S1106: A Randomized Phase II US
Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By
Autologous Stem Cell Transplant for Patients with Mantle Cell
Lymphoma |
https://ash.confex.com/ash/2018/webprogram/Paper112752.html |
2847 |
Enhanced Expression of FGF Signaling in Primary Central Nervous
System Lymphoma |
https://ash.confex.com/ash/2018/webprogram/Paper116416.html |
3434 |
Exploring LAG-3 Expression in Multiple Myeloma Patients Following
Autologous Stem Cell Transplant |
https://ash.confex.com/ash/2018/webprogram/Paper119577.html |
4123 |
The Tumor Microenvironment of Nodular Lymphocyte Predominant
Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from
Classical Hodgkin Lymphoma |
https://ash.confex.com/ash/2018/webprogram/Paper115836.html |
1570 |
Enhanced DNA Repair and Genomic Stability in HIV(+) Diffuse Large B
Cell Lymphoma of Germinal Center Origin |
https://ash.confex.com/ash/2018/webprogram/Paper116571.html |
1850 |
mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and
Lymph Node |
https://ash.confex.com/ash/2018/webprogram/Paper118264.html |
70 |
Early Prediction of Moderate-Severe Chronic GvHD By Immunity
Related Transcriptome |
https://ash.confex.com/ash/2018/webprogram/Paper119926.html |
2977 |
Clinical Features and Cell of Origin Subtyping Using Gene
Expression Profiling in HIV-Negative Patients with Primary Central
Nervous System Lymphoma |
https://ash.confex.com/ash/2018/webprogram/Paper110660.html |
1324 |
Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively
Disrupts Inflammasome and Extracellular Matrix Genes in Multiple
Myeloma |
https://ash.confex.com/ash/2018/webprogram/Paper120326.html |
1077 |
High-Throughput Mirna Analysis Suggests Pro-Inflammatory Profile in
Sickle Cell Disease |
https://ash.confex.com/ash/2018/webprogram/Paper110812.html |
355 |
ICOSL+ Plasmacytoid Dendritic Cells As Biomarker and Inducer
of Graft-Versus-Host Disease |
https://ash.confex.com/ash/2018/webprogram/Paper116417.html |
343 |
A New Stromal Signature Applicable to Formalin-Fixed
Paraffin-Embedded Tissues Identifies Patients at Risk in
Prospective Clinical Trials of the German High-Grade Non-Hodgkin
Lymphoma Study Group |
https://ash.confex.com/ash/2018/webprogram/Paper112450.html |
1621 |
A Critical Role for Intratumoral and Circulating LAG3 in Classical
Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III
International Clinical Trial |
https://ash.confex.com/ash/2018/webprogram/Paper112008.html |
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, IO
360, LymphMark, nCounter, and Prosigna are trademarks or registered
trademarks of NanoString Technologies, Inc. in various
jurisdictions.